Grant: Op Grant: Sex as a Biological Variable Supplement: COVID-19 Rapid Research FO
Unity Health Toronto
$50,000.00
Sex as a Biological Variable Supplement - Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)
FY 2020-21
Summary
An epidemic caused by a novel coronavirus (SARS-CoV-2) has spread rapidly in China and 27 other countries. As of 15 February 2020, over 69,000 cases of COVID-19 have been reported, with 1,666 deaths. The enormous health, economic and social impact clearly make it paramount to better understand the pathogenesis of COVID-19, as no specific drugs are available to combat COVID-19. To address this issue we have put together a world-class international research team of basic scientists and clinicians who have a track record of working together and have access to resources [SARS-CoV-2, cell and animal models, a candidate drug, biotech company, and patients (in China)].
This research proposal focuses on the role of angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor to enter human body. We propose to do basic studies to examine the specific mechanisms involved, as well as to perform a clinical trial in COVID-19 patients in China using recombinant human ACE2 (rhACE2).
Department
Program
Op Grant: Sex as a Biological Variable Supplement: COVID-19 Rapid Research FO
Recipient
Location
Ontario, Canada
Recipient Type
Other
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
424669
Name
Zhang Haibo
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
Sex as a Biological Variable Supplement - Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)
Programtype2
Operating Grants
Orgnameinp2
Unity Health Toronto
Cihramount2
$50,000
Cihrequipment2
$0
Programname2
Op Grant: Sex as a Biological Variable Supplement: COVID-19 Rapid Research FO
Keyworddelim
Biomedical Research; Development Of New Therapeutics
Abstract
An epidemic caused by a novel coronavirus (SARS-CoV-2) has spread rapidly in China and 27 other countries. As of 15 February 2020, over 69,000 cases of COVID-19 have been reported, with 1,666 deaths. The enormous health, economic and social impact clearly make it paramount to better understand the pathogenesis of COVID-19, as no specific drugs are available to combat COVID-19. To address this issue we have put together a world-class international research team of basic scientists and clinicians who have a track record of working together and have access to resources [SARS-CoV-2, cell and animal models, a candidate drug, biotech company, and patients (in China)].
This research proposal focuses on the role of angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor to enter human body. We propose to do basic studies to examine the specific mechanisms involved, as well as to perform a clinical trial in COVID-19 patients in China using recombinant human ACE2 (rhACE2).
Competitiondate
202004
Approvedterm2
1 yr 0 mth
Pinamesdelim
Zhang, Haibo; Mirazimi, Ali; Penninger, Josef; Slutsky, Arthur S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $50,000~ $0~